Cefepime

Cephalosporin Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefepime is an ofp drug in the Cephalosporin Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1996. DrugCentral lists 1 molecular target, including mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB. Recorded indications include Bacterial infection due to Klebsiella pneumoniae, Bacterial peritonitis, Bacterial pneumonia and Bacterial urinary infection.

• Approval status: ofp (first approved 1996 by the FDA).
• Drug class: Cephalosporin Antibacterial.
• Molecular targets: mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (1 listed in DrugCentral).
• Indications: Bacterial infection due to Klebsiella pneumoniae, Bacterial peritonitis, Bacterial pneumonia, Bacterial urinary infection and Complicated Bacteroides Peritonitis and others.
• ATC code: J01DE01 (Fourth-generation cephalosporins).
• Molecular formula: C19H24N6O5S2; molecular weight 480.57 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (25)

• Bacterial infection due to Klebsiella pneumoniae
• Bacterial peritonitis
• Bacterial pneumonia
• Bacterial urinary infection
• Complicated Bacteroides Peritonitis
• Complicated E. Coli Peritonitis
• Complicated Klebsiella Peritonitis
• Complicated Proteus UTI
• Complicated Streptococcus Peritonitis
• Complicated Urinary Tract Infections
• E. Coli Pyelonephritis
• Enterobacter Pneumonia
• Escherichia coli urinary tract infection
• Infection due to Pseudomonas aeruginosa
• Infection due to Staphylococcus aureus
• Infectious disease of abdomen
• Klebsiella cystitis
• Klebsiella Pyelonephritis
• Pneumococcal pneumonia
• Pneumonia due to Pseudomonas
• Pneumonia due to Streptococcus
• Proteus Pyelonephritis
• Proteus urinary tract infection
• Streptococcus pyogenes infection
• Urinary tract infection caused by Klebsiella

Contraindications (8)

• Blood coagulation disorder
• Colitis
• Disorder of brain
• Factor II deficiency
• Impaired renal function disorder
• Myoclonus
• Pseudomembranous enterocolitis
• Seizure disorder

Mechanism & targets

• Established pharmacologic class: Cephalosporin Antibacterial

Molecular targets (1)

Target	Gene	Action	Activity
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-01-18	FDA	—	HOSPIRA INC

ATC classification

ATC code	Therapeutic hierarchy
J01DE01	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Fourth-generation cephalosporins
J01DE51	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Fourth-generation cephalosporins
J01RA06	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Acute kidney injury	1146.1
Encephalopathy	1041.8
Febrile neutropenia	608.9
Drug reaction with eosinophilia and systemic symptoms	573.8
Neurotoxicity	512.9
Cytokine release syndrome	492.3
Septic shock	462.6
Multiple organ dysfunction syndrome	426.2
Respiratory failure	295.1
Sepsis	294.8
Acute generalised exanthematous pustulosis	274.8
Pyrexia	257.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cefepime is on its molecule page.

• Molecular formula: C₁₉H₂₄N₆O₅S₂
• Molecular weight: 480.57 g/mol
• CAS number: —
• InChIKey: HVFLCNVBZFFHBT-ZKDACBOMSA-N
• PubChem CID: 5479537

CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefepime used for?

DrugCentral lists the following indications for Cefepime: Bacterial infection due to Klebsiella pneumoniae, Bacterial peritonitis, Bacterial pneumonia, Bacterial urinary infection, Complicated Bacteroides Peritonitis, Complicated E. Coli Peritonitis, Complicated Klebsiella Peritonitis and Complicated Proteus UTI and others.

How does Cefepime work?

Its molecular targets in DrugCentral include mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (inhibitor).

When was Cefepime first approved?

Cefepime was first approved by the FDA in 1996.

What drug class does Cefepime belong to?

Cefepime is in the Cephalosporin Antibacterial class.

What is the chemical formula of Cefepime?

Cefepime has the molecular formula C19H24N6O5S2 and a molecular weight of 480.57 g/mol.

Sources

• DrugCentral drug card 535 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200962 — compound record and bioactivity
• PubChem CID 5479537 — chemical identifiers
• DrugBank DB01413 — drug record
• FDA UNII 807PW4VQE3 — substance identity
• DailyMed: FDA labels for Cefepime — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.